EPRX
NASDAQ HealthcareEupraxia Pharmaceuticals Inc. - Common Stock
Biotechnology
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
๐ Market Data
| Price | $7.89 |
|---|---|
| Volume | 262,377 |
| Market Cap | 485.26M |
| Beta | 1.420 |
| RSI (14-Day) | 67.3 |
| 200-Day MA | $6.66 |
| 50-Day MA | $7.44 |
| 52-Week High | $9.32 |
| 52-Week Low | $3.67 |
| Forward P/E | -11.86 |
| Price / Book | 7.84 |
๐ฏ Investment Strategy Scores
EPRX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (78/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EPRX in your text
Paste any article, transcript, or post โ the tool will extract EPRX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.